Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.25
DNDN's Cash to Debt is ranked lower than
51% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. DNDN: 0.25 )
DNDN' s 10-Year Cash to Debt Range
Min: 0.25   Max: No Debt
Current: 0.25

Equity to Asset -0.72
DNDN's Equity to Asset is ranked lower than
53% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. DNDN: -0.72 )
DNDN' s 10-Year Equity to Asset Range
Min: -0.72   Max: 0.94
Current: -0.72

-0.72
0.94
F-Score: 3
Z-Score: -7.84
M-Score: -4.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -85.65
DNDN's Operating margin (%) is ranked higher than
70% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. DNDN: -85.65 )
DNDN' s 10-Year Operating margin (%) Range
Min: -99050.5   Max: -85.39
Current: -85.65

-99050.5
-85.39
Net-margin (%) -104.60
DNDN's Net-margin (%) is ranked higher than
69% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. DNDN: -104.60 )
DNDN' s 10-Year Net-margin (%) Range
Min: -217981.19   Max: -98.89
Current: -104.6

-217981.19
-98.89
ROA (%) -68.32
DNDN's ROA (%) is ranked higher than
57% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. DNDN: -68.32 )
DNDN' s 10-Year ROA (%) Range
Min: -86.17   Max: -14.67
Current: -68.32

-86.17
-14.67
ROC (Joel Greenblatt) (%) -155.51
DNDN's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. DNDN: -155.51 )
DNDN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1276.47   Max: -96.83
Current: -155.51

-1276.47
-96.83
Revenue Growth (%) 74.80
DNDN's Revenue Growth (%) is ranked higher than
98% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. DNDN: 74.80 )
DNDN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 227.1
Current: 74.8

0
227.1
EBITDA Growth (%) -23.10
DNDN's EBITDA Growth (%) is ranked higher than
64% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. DNDN: -23.10 )
DNDN' s 10-Year EBITDA Growth (%) Range
Min: -61.8   Max: 343.1
Current: -23.1

-61.8
343.1
EPS Growth (%) -15.00
DNDN's EPS Growth (%) is ranked higher than
73% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. DNDN: -15.00 )
DNDN' s 10-Year EPS Growth (%) Range
Min: -61.5   Max: 43
Current: -15

-61.5
43
» DNDN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

DNDN Guru Trades in Q2 2013

Steven Cohen 4,000,000 sh (+1034.43%)
Murray Stahl 34,000 sh (+17.24%)
PRIMECAP Management 3,770,700 sh (-0.5%)
» More
Q3 2013

DNDN Guru Trades in Q3 2013

Murray Stahl 34,000 sh (unchged)
Steven Cohen 3,677,000 sh (-8.08%)
PRIMECAP Management 3,069,700 sh (-18.59%)
» More
Q4 2013

DNDN Guru Trades in Q4 2013

Paul Tudor Jones 76,049 sh (New)
Murray Stahl 34,000 sh (unchged)
PRIMECAP Management 3,069,700 sh (unchged)
Steven Cohen 1,421,700 sh (-61.34%)
» More
Q1 2014

DNDN Guru Trades in Q1 2014

Murray Stahl 34,000 sh (unchged)
PRIMECAP Management 3,069,700 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DNDN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-09-30 Sold Out 0.13%$4.27 - $7.43 $ 2.14-61%0
PRIMECAP Management 2012-09-30 Reduce -28.95%0.02%$4.27 - $7.43 $ 2.14-61%4427800
PRIMECAP Management 2012-06-30 Reduce -28.51%0.04%$5.83 - $11.8 $ 2.14-75%6231930
John Burbank 2012-03-31 New Buy0.18%$7.6 - $16.53 $ 2.14-82%500000
George Soros 2011-12-31 Sold Out 0.03%$6.55 - $11.29 $ 2.14-75%0
George Soros 2011-09-30 Reduce -92.85%1.33%$9.12 - $41.64 $ 2.14-90%185000
George Soros 2011-06-30 Reduce -44.64%1.22%$36.86 - $43.43 $ 2.14-95%2586366
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Dendreon Corp

An Ocean of 52-Week Lows - 50% Off High, Second Quarter Financials
The GuruFocus special feature 52-week low Value Screen is a great research tool to help investors quickly sort through the 740 USA stocks currently listed at a 52-week low, not to mention thousands of other stocks around the world. Read more...

Ratios

vs
industry
vs
history
P/S 1.20
DNDN's P/S is ranked higher than
98% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. DNDN: 1.20 )
DNDN' s 10-Year P/S Range
Min: 1.04   Max: 5406
Current: 1.2

1.04
5406
EV-to-EBIT -3.79
DNDN's EV-to-EBIT is ranked higher than
77% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. DNDN: -3.79 )
DNDN' s 10-Year EV-to-EBIT Range
Min: 22.3   Max: 213.4
Current: -3.79

22.3
213.4
Current Ratio 2.57
DNDN's Current Ratio is ranked higher than
64% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. DNDN: 2.57 )
DNDN' s 10-Year Current Ratio Range
Min: 1.13   Max: 15.22
Current: 2.57

1.13
15.22
Quick Ratio 1.95
DNDN's Quick Ratio is ranked higher than
62% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. DNDN: 1.95 )
DNDN' s 10-Year Quick Ratio Range
Min: 1.02   Max: 15.22
Current: 1.95

1.02
15.22

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.10
DNDN's Price/Median PS Value is ranked higher than
99% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. DNDN: 0.10 )
DNDN' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 119.74
Current: 0.1

0.11
119.74
Earnings Yield (Greenblatt) 1305.30
DNDN's Earnings Yield (Greenblatt) is ranked higher than
98% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. DNDN: 1305.30 )
DNDN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 1440.4
Current: 1305.3

0.5
1440.4
Forward Rate of Return (Yacktman) -66.18
DNDN's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. DNDN: -66.18 )
DNDN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13   Max: 23.6
Current: -66.18

-13
23.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DNR.Germany
Dendreon Corp, a Delaware corporation, is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients. Its product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration, and is a first in class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second cause of cancer deaths in men in the United States. The Company owns worldwide rights for PROVENGE. The other potential product candidates are under development or are evaluating include investigational cellular immunotherapies targeted towards HER2/neu for the treatment of patients with bladder, breast, ovarian and other solid tumors, carbonic anhydrase 9 ('CA9'), an antigen highly expressed in renal cell carcinoma; and carcinoembryonic antigen ("CEA"), an antigen expressed in colorectal and other cancers. In addition, the Company is investigating an orally-available small molecule treatment targeting TRPM8 that could be applicable to multiple types of cancer in advanced cancer patients. The Company currently depends on specialized vendor relationships that are not readily replaceable for some of the components for its active immunotherapy candidates. Products such as chemotherapeutics, androgen metabolism or androgen receptor antagonists, endothelin A receptor antagonists, antisense compounds, angiogenesis inhibitors and gene therapies for cancer are also under development by a number of companies and could potentially compete with PROVENGE and its other product candidates. The Company's competitors include major pharmaceutical companies. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. The Company is also subject to regulation by the Occupational Safety and Health Administration ('OSHA'), and the Environmental Protection Agency ('EPA'), and to regulation under the Toxic Substances Control Act.
» More Articles for DNDN

Headlines

Articles On GuruFocus.com
Why You Should Buy Dendreon's Drop Jul 19 2014 
An Ocean of 52-Week Lows - 50% Off High, Second Quarter Financials Aug 11 2013 
Idenix: Strong Pipeline Will Reward Investors Apr 24 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Dendreon Could Slip On Shrinking Market For Provenge Apr 22 2012 
Weekly Guru Bargains Highlights: DNDN, AUQ, RFMD, PT, INFA Jan 16 2012 
Weekly Guru Bargains Highlights: FTR, HUN, HFC, DNDN, PEGA Jan 09 2012 
Options III: Strategy for the Long Term - Writing Covered Calls Oct 17 2011 
Thursday Value Overview Aug 04 2011 
Wednesday Value Overview Jul 27 2011 


More From Other Websites
3 Convincing Reasons To Buy Dendreon Jul 24 2014
New Provenge Data: Why Deerfield Investments Acquired A More Than 5% Stake In May Jul 07 2014
What Does Dendreon Need To Succeed? Jul 07 2014
Dendreon (DNDN) Stock Has Huge Short Interest: Time to Cover? Jun 26 2014
Dendreon May Still Be In Play Jun 24 2014
3 Terrific Reasons To Buy Dendreon Jun 18 2014
Dendreon: An Update On The Debt Situation Jun 18 2014
DENDREON CORP Files SEC form 8-K, Termination of a Material Definitive Agreement Jun 18 2014
[$$] Dendreon's Dreaded Outlook Jun 11 2014
Dendreon's CEO Departs at Critical Juncture Jun 10 2014
Is Dendreon Done? Jun 10 2014
Dendreon CEO Leaves: Buyout Or Bankruptcy? Jun 09 2014
Dendreon CEO Johnson Resigns as Provenge Overtaken by Rivals Jun 09 2014
Dendreon CEO Exits Ahead of Big Debt Payment Jun 09 2014
DENDREON CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jun 09 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide